Global Preliminary Screening Tests Market, By Product (Over-the-Counter (OTC) Rapid Test Product, Professional Rapid Test Product), Application (Infectious Disease, Cardiology, Oncology, Pregnancy and Fertility, Toxicology, Glucose Monitoring, Others), End User (Hospital and Clinic, Diagnostic Laboratory, Home Care, Others) – Industry Trends and Forecast to 2030.
Preliminary Screening Tests Market Analysis and Size
According to World Health Organization (WHO) studies, seasonal influenza result in around 3 - 5 million cases of severe illness across the globe every year. Growing adoption of novel influenza diagnostic techniques and launching innovative rapid influenza tests by major market players are creating lucrative opportunities for market growth during the forecast period of 2023-2030.
Data Bridge Market Research analyses that the preliminary screening tests market which was USD 2.8 billion in 2022, is expected to reach USD 9.18 billion by 2030, at a CAGR of 16% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Preliminary Screening Tests Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Over-the-Counter (OTC) Rapid Test Product, Professional Rapid Test Product), Application (Infectious Disease, Cardiology, Oncology, Pregnancy and Fertility, Toxicology, Glucose Monitoring, Others), End User (Hospital and Clinic, Diagnostic Laboratory, Home Care, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Akers Biosciences, Inc. (U.S.), Abbott (U.S.), BD (U.S.), Bio-rad Laboratories, Inc. (U.S.), Cepheid (U.S.), Hologic Inc. (U.S.), Meridian Bioscience, Inc. (U.S.), OraSure Technologies, Inc. (U.S.), Quidel Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BUREAU VERITAS (U.S.), Eurofins Scientific (Luxembourg), Siemens Healthcare Private Limited (Germany), Luminex Corporation (U.S.), PerkinElmer Inc. (U.S.), QIAGEN (Germany), Mesa Biotech (U.S.), Illumina, Inc (U.S.)
|
|
Market Opportunities
|
|
Market Definition
A preliminary screening is a breath or saliva test administered by a law enforcement officer to determine whether an arrest should be made and whether an evidentiary test should be requested. Preliminary screening results may not be used as evidence of impairment in any court proceeding.
Global Preliminary Screening Tests Market Dynamics
Drivers
- Surging volume of patients suffering from various disorders
The rising number of patients suffering from cardiovascular disorders and other diseases, the increasing benefits of rapid testing over laboratory testing, the increasing number of initiatives by the government and private organisations aimed at the growth of the healthcare sector, rising levels of health expenditure globally, and favourable government policies are some of the impactful factors that are likely to accelerate the growth of the preliminary screening tests market.
On the other hand, an increasing number of applications from emerging economies, as well as the stability of the test at high temperatures and the shorter time required to initiate the test, will create new and abundant opportunities, leading to the growth of the preliminary screening tests market in the forecast period.
- Rise in prevalence of influenza
The global market is anticipated to grow as influenza prevalence rises. The centres for disease control and prevention (CDC) predicts that influenza causes somewhere between 12,000 and 79,000 fatalities annually in the United States. The market is also anticipated to develop throughout the forecast period as awareness of the value of early identification and prevention of diseases like influenza increases.
Opportunities
- Increase in the number of research and development activities
It is anticipated that increasing R&D spending will boost the global adoption rates of these diagnostic tests by providing technologically sophisticated solutions to identify influenza. The widespread use of quick diagnostic testing and the rising influenza prevalence will drive the market revenue for these tests in the upcoming years.
Restraints/Challenges
- High cost of the test
The high cost of the test, as well as its limited availability in developing economies and a lack of trained personnel, will likely limit the growth of the preliminary screening tests market during the forecast period. Stringent regulatory standards for test approval, combined with technical failure, will be the market's most significant and immediate challenge.
This preliminary screening tests market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the preliminary screening tests market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Preliminary Screening Tests Market Scope
The preliminary screening tests market is segmented on the basis of product, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Over-the-Counter (OTC) Rapid Test Product
- Professional Rapid Test Product
Application
- Infectious Disease
- HPV
- Hepatitis
- Influenza
- Malaria
- HIV
- Others
- Cardiology
- Oncology
- Pregnancy and Fertility
- Toxicology
- Glucose Monitoring
- Others
End User
- Hospital and Clinic
- Diagnostic Laboratory
- Home Care
- Others
Preliminary Screening Tests Market Regional Analysis/Insights
The preliminary screening tests market is analyzed and market size insights and trends are provided by country, product, application, and end user as referenced above.
The countries covered in the preliminary screening tests market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the preliminary screening tests market due to the growth of the healthcare sector along with availability of quick and fast service during the time of emergency.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the high occurrences of infectious diseases along with development of healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The preliminary screening tests market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for preliminary screening tests market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the preliminary screening tests market. The data is available for historic period 2011-2021.
Competitive Landscape and Preliminary Screening Tests Market Share Analysis
The preliminary screening tests market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to preliminary screening tests market.
Some of the major players operating in the preliminary screening tests market are:
- Akers Biosciences, Inc. (U.S.)
- Abbott (U.S.)
- BD (U.S.)
- Bio-rad Laboratories, Inc. (U.S.)
- Cepheid (U.S.)
- Hologic Inc. (U.S.)
- Meridian Bioscience, Inc. (U.S.)
- OraSure Technologies, Inc. (U.S.)
- Quidel Corporation (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- BUREAU VERITAS (U.S.)
- Eurofins Scientific (Luxembourg)
- Siemens Healthcare Private Limited (Germany)
- Luminex Corporation (U.S.)
- PerkinElmer Inc. (U.S.)
- QIAGEN (Germany)
- Mesa Biotech (U.S.)
- Illumina, Inc (U.S.)
SKU-